Crescent Biopharma (CBIO) Return on Sales (2013 - 2026)

Crescent Biopharma (CBIO) has 10 years of Return on Sales data on file, last reported at 0.22% in Q1 2026.

• Return on Sales for Q1 2026 came in at 0.22%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 1.54% (changed N/A YoY), and the FY2025 annual result was 0.14%, changed N/A from the prior year.
• Return on Sales rose to 0.22% in Q1 2026 per CBIO's latest filing, from 5.51% in the prior quarter.
• Over five years, Return on Sales peaked at 0.22% in Q1 2026 and troughed at 5.51% in Q4 2024.
• A 3-year average of 3.11% and a median of 3.01% in 2022 frame the typical range for Return on Sales.
• On a YoY basis, Return on Sales climbed as much as 101226 bps in 2022 and fell as far as 100 bps in 2022.
• A 3-year view of Return on Sales shows it stood at 5.04% in 2022, then decreased by 9 bps to 5.51% in 2024, then jumped by 96 bps to 0.22% in 2026.
• Business Quant data shows CBIO's Return on Sales at 0.22% in Q1 2026, 5.51% in Q4 2024, and 5.04% in Q4 2022.